Taysha Gene Therapies Posts $39.1M Q3 Loss, $422.8M Cash

Taysha Gene Therapies (Nasdaq: TSHA) reported a net loss of $39.1 million, or $0.10 per share, for the third quarter ended September 30, 2026, on November 12, 2026, alongside $422.8 million in cash and cash equivalents. Research and development expenses rose to $28.8 million from $25.7 million a year earlier, while general and administrative costs climbed to $13.1 million from $8.3 million. The clinical-stage biotech said its current cash resources will fund planned operating expenses and capital requirements into the second half of 2028.

Context — Why Taysha's Q3 2026 Cash Position Matters Now

Taysha is spending against a single lead asset, TSHA-102, an investigational gene therapy for Rett syndrome. The company said the third quarter's higher research and development costs were driven primarily by clinical expenses from its REVEAL Part A Phase 1/2, REVEAL Part B pivotal and ASPIRE trials. Compensation expenses, including non-cash stock-based compensation, also rose on additional research and development headcount.

The prior-year comparison shows the scale of the build. Research and development expenses for the three months ended September 30, 2025, were $25.7 million, meaning the 2026 quarter ran $3.1 million higher. General and administrative expenses for the same 2025 period were $8.3 million, so the $13.1 million 2026 figure represents an increase of $4.8 million.

The company attributed the administrative increase to higher compensation, including non-cash stock-based compensation, plus increases in consulting and professional fees tied to commercial launch-readiness initiatives. That spending pattern is consistent with a company preparing for a potential regulatory filing rather than one still in early discovery.

Taysha said it completed a BLA-enabling Process Performance Qualification manufacturing campaign for TSHA-102 following alignment with the U.S. Food and Drug Administration on its proposed PPQ strategy. The company said all process parameters and analytical results met predefined product specifications as well as comparability criteria for commercial product and clinical material.

Taysha also said the final commercial manufacturing process consistently achieved a single-digit empty capsid percentage, which it described as an important indicator of product quality contributing to patient safety. The company said the PPQ results demonstrate process consistency and scalability required to support potential commercial demand.

Data — What the Numbers Show

For the three months ended September 30, 2026, total operating expenses were $41.9 million against $34.0 million a year earlier. Loss from operations widened to $41.9 million from $34.0 million. Total other income, net, was $2.7 million versus $1.3 million in the prior-year quarter, helped by interest income of $3.9 million compared with $3.2 million.

The nine-month picture shows a larger step-up. Research and development expenses were $101.2 million for the nine months ended September 30, 2026, against $61.5 million for the same period in 2025. General and administrative expenses were $34.9 million versus $25.0 million. Net loss for the nine months was $128.2 million, or $0.34 per share, compared with $81.1 million, or $0.26 per share, a year earlier.

Metric	Q3 2026	Q3 2025
Research and development	$28.8M	$25.7M
General and administrative	$13.1M	$8.3M
Net loss	$39.1M	$32.7M
Net loss per share	$0.10	$0.09

The balance sheet carried $422.8 million in cash and cash equivalents as of September 30, 2026, up from $319.8 million at December 31, 2025. Total assets were $435.0 million against $343.3 million at year-end 2025. Total liabilities fell to $78.1 million from $96.4 million, and total stockholders' equity rose to $357.0 million from $246.9 million.

The company reported no revenue for the third quarter and nine months of 2026, compared with $4.3 million of revenue in the nine months ended September 30, 2025. The report did not disclose the source of that prior-year revenue.

Analysis — What It Means for Biotech and Gene Therapy Names

Taysha's cash position is the central fact for equity holders. A $422.8 million balance against a quarterly net loss of $39.1 million gives the company a runway the report itself extends into the second half of 2028, which covers the expected readout windows for its pivotal program. That removes near-term financing pressure from the story and shifts the debate entirely to clinical and regulatory outcomes.

The safety dataset is the second anchor. Taysha said high dose and low dose TSHA-102 continued to be generally well tolerated with no severe treatment-related serious adverse events or dose-limiting toxicities across the REVEAL Phase 1/2, REVEAL pivotal and ASPIRE trials, covering 33 patients as of the November 2026 data cutoff. The company said all patients in those trials cleared the acute post-dosing safety monitoring period typically associated with AAV gene therapies.

The counter-argument is that this remains a single-asset story with no approved product and no current revenue. The safety read is a tolerability statement, not an efficacy statement, and the company has not yet reported the functional endpoints that would drive a labeling discussion. Manufacturing success reduces one risk but does not substitute for clinical benefit.

Positioning reflects that asymmetry. Holders are effectively long a binary regulatory and efficacy catalyst set for 2027, while the cash cushion limits forced-selling risk. The stock's sensitivity now sits with trial data and FDA correspondence rather than with quarterly expense lines, which are tracking the company's own build-out plan.

Outlook — What to Watch Next

Taysha listed three dated milestones. FDA feedback following a CMC Type B meeting is expected in the first quarter of 2027. Topline data from the REVEAL pivotal trial's six-month interim analysis, plus FDA feedback on the BLA submission pathway for TSHA-102, are both expected in the first half of 2027. The company also said it expects to nominate an additional gene therapy development candidate targeting a CNS disorder and commence preclinical development activities in the first half of 2027.

The company said it plans to discuss the CMC data in an anticipated meeting with FDA in the fourth quarter of 2026 to further strengthen the CMC package for the potential BLA submission. Taysha also said it presented encore data supporting the TSHA-102 clinical program at the 55th Child Neurology Society Annual Meeting, covering material previously presented at the 2026 International Rett Syndrome Foundation Scientific Meeting.

Taysha did not disclose the terms of any financing, partnership or pricing arrangement in the report. Investors tracking the name through the healthcare coverage and equities sections should treat the 2027 readouts as the events that reset the thesis.

Frequently Asked Questions

How long can Taysha fund itself at the current burn rate?

Taysha reported $422.8 million in cash and cash equivalents as of September 30, 2026, and said its current cash resources will support planned operating expenses and capital requirements into the second half of 2028. That guidance covers the expected first-half 2027 REVEAL pivotal interim data readout and FDA feedback on the BLA pathway. The company did not disclose a specific quarterly burn projection beyond its reported expense lines.

What did Taysha's manufacturing campaign actually achieve?

The company said its BLA-enabling PPQ campaign for TSHA-102 met predefined product specifications and comparability criteria for commercial product and clinical material, and consistently achieved a single-digit empty capsid percentage. Taysha said these results support potential inclusion of REVEAL Part A Phase 1/2 data in the planned BLA submission and demonstrate process consistency and scalability for potential commercial demand.

Why did Taysha's net loss widen year over year?

The wider loss tracked higher operating expenses rather than a revenue shortfall. Research and development rose $3.1 million and general and administrative costs rose $4.8 million versus the prior-year quarter, driven by trial activity across REVEAL and ASPIRE, added headcount and commercial launch-readiness spending. Those increases outpaced a $0.7 million rise in interest income, leaving the net loss $6.4 million wider.

Bottom Line

Taysha's $422.8 million cash pile funds operations into 2028, making 2027 trial and FDA readouts the only catalysts that matter.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.